Progress on adjuvant treatment of drug-resistant tuberculosis

doi:10.3969/j.issn.2095-3755.2013.04.002

Abstract

Abstract: Drug-resistant tuberculosis (TB) is the keystone and difficulty in TB control at home and abroad. In recent years, many scholars have applied immune agents in the adjuvant treatment of drug-resistant TB and obtained positive efficacy. Currently the most active research of immune agents are cytokines and mycobacterial vaccine formulations. However, the effects of these immune agents in the treatment of drug resistant TB are different, some have achieved good results, but others have no obvious effect. The paper reviews the leukemia cytokine and other immune agents that play an immunotherapy role in the adjuvant treatment of drug resistant TB, and it is anticipated to provide reference for the application of immune agents in the adjuvant treatment of drug resistant TB.

ZENG Xi-ling, CHU Nai-hui, LIU Zhi-min. Progress on adjuvant treatment of drug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Health , 2013, 2(4): 222-227. doi: 10.3969/j.issn.2095-3755.2013.04.002

References

[1] World Health Organization. Global tuberculosis report 2013[M/OL]. Geneva: World Health Organization, 2013(2013-10-23)[2013-11-16]. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
[2] Zhao Y, Xu S,Wang L,et al. National survey of drug-resistant tuberculosis in China.N Engl J Med, 2012, 366(23):2161-2170.
[3] 杜建,徐彩红,李琦,等. 不同类型治疗方案治疗耐多药结核病效果文献分析.中国防痨杂志,2010,32(8):421-426.
[4] Johnson BJ, Estrada I, Shen Z, et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immun, 1998,66(6):2426-2433.
[5] 中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2011年)(第二部分结核病临床治疗). 中国防痨杂志,2012,34(7):463-471.
[6] Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone.I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol, 1986, 136(7): 2348-2357.
[7] Hartmann P, Plum G. Immunological defense mechanisms in tuberculosis and MAC-infection. Diagn Microbiol Infect Dis,1999,34(2):147-152.
[8] Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol, 1989, 7:145-173.
[9] Erb KJ, Kirman J, Delahunt B, et al. Infection of mice with Mycobacterium bovis-BCG induces both Th1 and Th2 immune responses in the absence of interferon-gamma signalling. Eur Cytokine Netw, 1999,10(2):147-154.
[10] Somoskvi A, Zissel G, Zipfel PF, et al. Different cytokine patterns correlate with the extension of disease in pulmonary tuberculosis. Eur Cytokine Netw,1999,10(2):135-142.
[11] Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev, 2003,8(3):223-246.
[12] 王琳,蔡映云,程秋兰,等.肺结核患者的Th1/Th1细胞因子失衡. 中华结核和呼吸杂志,2002,25(9):535-537.
[13] Casarini M, Ameglio F, Alemanno L, et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med, 1999, 159(1):143-148.
[14] 尹洪云,何娅,杨研,等. 肺结核患者外周血自然杀伤细胞和T细胞数量和细胞因子水平变化. 中国防痨杂志,2009,31(12):725-727.
[15] 李其林. 白介素-2对预防尖锐湿疣复发的研究. 中国皮肤性病学杂志, 1998, 12 (5):289-291.
[16] 徐纪茹,张京田,李选社. 肺结核患者白细胞介素-2及其受体的研究.中华结核和呼吸杂志,1992,15(1):38-39.
[17] 李红,唐神结. 肺结核患者外周血sIL-2R、TNF-α、IFN-γ、IL-6的检测及意义. 中国防痨杂志,2011,33(1):57-60.
[18] 邱奕,赵善民,师长宏,等. 复苏促生长因子结构域及其突变体重组蛋白诱导小鼠免疫应答的研究. 中国防痨杂志,2013,35(5):331-336.
[19] 初乃惠,朱莉贞,叶志忠,等.重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察.中华结核和呼吸杂志,2003,26(9):548-551.
[20] Zhang Y, Liu J, Wang Y, et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci, 2012, 55(9):800-806.
[21] 徐俊彦,吴斌. 重组人白细胞介素2辅助治疗肺结核的探讨. 国际医药卫生导报,2004,10(14):51-52.
[22] 余连锋,朱杰,许坚,等. 重组人白细胞介素-2辅助治疗复治肺结核疗效观察. 现代实用医学,2008,20(7): 542-543.
[23] Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med, 2003, 168(2): 185-191.
[24] Cooper AM, Khader SA. The ro1e of cytokines in the initiation,expansion,and control of cellular immunity to tuberculosis.Immunol Rev, 2008, 226:191-204.
[25] 梁莉,乐军,刘丽蓉,等.γ干扰素和转化生长因子β水平与支气管结核治疗效果的关联性研究. 中国防痨杂志,2011,33(11):703-706.
[26] 李丹,杜德兵,邱绍勤,等.γ-干扰素联合微卡免疫治疗结核病小鼠的实验研究.中国防痨杂志,2008,30(6):510-514.
[27] Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med,1993,178(6):2249-2254.
[28] 王琳,汪学智,程秋兰,等. 肌注重组IFN-γ联合抗结核药治疗肺结核的效果. 中国防痨杂志,2006,28(2):77-79.
[29] 林存智,张海燕,戚艳,等. 雾化吸入重组人γ干扰素治疗复治耐多药肺结核的临床研究//中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 全国复治肺结核诊断与治疗进展研讨会论文汇编,贵阳,2010. 北京:中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会,2010:61.
[30] Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet,1997,349(9064):1513-1515.
[31] Suárez-Méndez R, García-García I, Fernández-Olivera N, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis, 2004, 4:44.
[32] Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resis-tant pulmonary tuberculosis. J Korean Med Sci, 2004, 19(2):167-171.
[33] Park SK, Cho S, Lee IH, et al. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. BMC Infect Dis, 2007,11(5):434-440.
[34] Lee JY, Yim JJ, Yoon BW. Adjuvant interferon-γ treatment in two cases of refractory tuberculosis of the brain. Clin Neurol Neurosurg, 2012,114(6): 732-734.
[35] Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon -gamma for the treatment of pulmonary tuberculosis: a syste-matic review. Int J Infect Dis,2011,15(9):e594-600.
[36] Giosué S, Casarini M, Alemanno L, et al. Effects of aeroso-lized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Grit Care Med, 1998,158(4):1156-1162.
[37] 邓志海. 含α-干扰素方案治疗70例复治涂阳肺结核疗效分析.传染病信息, 2006,19(1):42.
[38] Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacte-rium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One, 2012, 7(7):e39215.
[39] Gupta A, Ahmad FJ, Ahmad F, et al. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine, 2012, 30(43):6198-6209.
[40] Faujdar J, Gupta P, Natrajan M, et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res, 2011,134(5):696-703.
[41] Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One, 2011,6(9):e23826.
[42] Dlugovitzky D, FiorenzaG, Farroni M, et al. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir Med, 2006,100(6):1079-1087.
[43] Butov DA, Efremenko YV, Prihoda ND, et al. Adjunct immune therapy for first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunothe-rapy, 2012, 4(7):687-695.
[44] 陈尊杰, 符慧, 黄钥藩. 胸腺肽联合抗结核药治疗复治涂阳肺结核临床观察.实用医学杂志, 2012, 28(14):2437-2438.